Sanofi 1Q Exceeds Expectations, Beyfortus Drug Launch in Focus -- Market Talk

Dow Jones04-25

1316 GMT - Sanofi's 1Q beat sales and profit expectations thanks to the performance of anti-inflammatory drug Dupixent and the better-than-expected launch of lung disease treatment Beyfortus, Jefferies analyst Peter Welford says in a note. The French pharma giant's vaccines were shy of consensus despite being boosted by its Beyfortus beat, he says. Sanofi saw a lower gross margin which was more than offset by a higher-than-expected business operating income and EPS, Jefferies says. Jefferies expected Sanofi to confirm its 2024 guidance and says it is less pessimistic than the market regarding a potential rebound in its gross margin in 2025. Shares rise 2.1% to EUR89.67. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 25, 2024 09:30 ET (13:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430428570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-25 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430428570","market":"fut","top_or_hot":-1,"title":"Sanofi 1Q Exceeds Expectations, Beyfortus Drug Launch in Focus -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1316 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s 1Q beat sales and profit expectations thanks to the performance of anti-inflammatory drug Dupixent and the better-than-expected launch of lung disease treatment Beyfortus, Jefferies analyst Peter Welford says in a note. The French pharma giant's vaccines were shy of consensus despite being boosted by its Beyfortus beat, he says. Sanofi saw a lower gross margin which was more than offset by a higher-than-expected business operating income and EPS, Jefferies says. Jefferies expected Sanofi to confirm its 2024 guidance and says it is less pessimistic than the market regarding a potential rebound in its gross margin in 2025. Shares rise 2.1% to EUR89.67. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 25, 2024 09:30 ET (13:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi 1Q Exceeds Expectations, Beyfortus Drug Launch in Focus -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi 1Q Exceeds Expectations, Beyfortus Drug Launch in Focus -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1316 GMT - Sanofi's 1Q beat sales and profit expectations thanks to the performance of anti-inflammatory drug Dupixent and the better-than-expected launch of lung disease treatment Beyfortus, ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2430428570","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430428570","pubTimestamp":1714051800,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1316 GMT - Sanofi's 1Q beat sales and profit expectations thanks to the performance of anti-inflammatory drug Dupixent and the better-than-expected launch of lung disease treatment Beyfortus, Jefferies analyst Peter Welford says in a note. The French pharma giant's vaccines were shy of consensus despite being boosted by its Beyfortus beat, he says. Sanofi saw a lower gross margin which was more than offset by a higher-than-expected business operating income and EPS, Jefferies says. Jefferies expected Sanofi to confirm its 2024 guidance and says it is less pessimistic than the market regarding a potential rebound in its gross margin in 2025. Shares rise 2.1% to EUR89.67. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","BK4588":"碎股","BK4007":"制药","SNYNF":"Sanofi"},"translate_title":"赛诺菲1Q超越预期，Beyfortus药物上市聚焦——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9},"content_text":"1316 GMT - Sanofi's 1Q beat sales and profit expectations thanks to the performance of anti-inflammatory drug Dupixent and the better-than-expected launch of lung disease treatment Beyfortus, Jefferies analyst Peter Welford says in a note. The French pharma giant's vaccines were shy of consensus despite being boosted by its Beyfortus beat, he says. Sanofi saw a lower gross margin which was more than offset by a higher-than-expected business operating income and EPS, Jefferies says. Jefferies expected Sanofi to confirm its 2024 guidance and says it is less pessimistic than the market regarding a potential rebound in its gross margin in 2025. Shares rise 2.1% to EUR89.67. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 25, 2024 09:30 ET (13:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430428570"}